Prodotti competitors / Area Onco-Ema
CHMP recommended granting a Conditional Marketing Authorisation for Elrexfio (elranatamab) for the treatment of adult patients with relapsed or refractory multiple myeloma.
![Immagine News](/media/l4el5htd/cat-2.jpg?anchor=center&mode=crop&width=722&height=442)
On 13 October 2023, the CHMP released its Positive recommendations on new medicine
- Elrexfio (elranatamab) - Pfizer
The committee recommended granting a Conditional Marketing Authorisation for Elrexfio (elranatamab), for the treatment of adult patients with relapsed or refractory multiple myeloma.
Indication:
Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
Grazie per il tuo feedback!